Multiple Sclerosis Drugs
Multiple Sclerosis Drugs

Multiple Sclerosis Drugs Comprehensive Study by Type (Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Primary-Progressive MS (PPMS), Secondary-Progressive MS (SPMS)), Route of Administration (Injectable, Oral), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2026

Multiple Sclerosis Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 208 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Multiple Sclerosis Drugs Market Overview:
Multiple sclerosis (MS) is a neurological disease that affects the brain and spinal cord. The myelin sheath is affected by multiple sclerosis. The word "myelin sheath" refers to the material that covers and protects human nerve cells. Multiple sclerosis symptoms are caused by this damage, which blocks signals between the brain and the body. Depending on where the infected nerve fibres are located, signs and symptoms can vary widely from person to person and throughout the course of the disease. Symptoms of these can affect the movement like Numbness or weakness in one or more limbs that typically occurs on one side of your body at a time, or your legs and trunk, Certain neck movements, especially bending the neck forward, cause electric shock sensations. It can also cause vison problems like blurry vision or partial loss of vision. Other Symptoms include Slurred speech, Fatigue, Dizziness, Tingling or pain in parts of your body, Problems with sexual, bowel and bladder function. The majority of people with MS experience relapsing-remitting symptoms. They have relapses or cycles of new symptoms that last days or weeks and then recover partially or fully. Following these relapses, quiet periods of disease remission may last months or even years. The drugs used to treat this are called Multiple Sclerosis Drugs

Growth Drivers
  • Growing instances of Multiple Sclerosis
  • Increasing Awareness about health problems among people

Market Trends
  • Increased Spending on Health


Opportunities
  • Increased Investment in R&D
  • Increasing Need For Better Multiple Sclerosis Treatment Options

Challenges
  • Side Effects of Multiple Sclerosis Medication


Competitive Landscape:

Some of the key players profiled in the report are Bristol Myers Squibb (United States), Genzyme Corporation (United States), Teva Pharmaceuticals (United States), Roche Holding AG (Switzerland), Merck KGaA (Germany), Mallinckrodt (Unite States), Pfizer Inc (United States), Hikma Pharmaceuticals PLC (United Kingdom), Par Pharmaceuticals (United States) and Cipla (India). Analyst at AMA Research see United States Players to retain maximum share of Global Multiple Sclerosis Drugs market by 2026. Considering Market by Route of Administration, the sub-segment i.e. Injectable will boost the Multiple Sclerosis Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Online will boost the Multiple Sclerosis Drugs market.

Latest Market Insights:
In August 2020, Genzyme Corporation signed acquisition agreement with Principia Biopharma Inc. a company engaged in the development of treatment solutions for immune mediated disease. This acquisition helped the company to enhance its research activities in the field of multiple sclerosis among other immune mediated disease.

January 2020 - Bristol Myers Squibb announced the launch of Zeposia, which is now the lowest priced oral MS drug available in the market.

The FDA is also requiring the makers of gadolinium contrast agents to conduct research to determine if there are harmful effects of gadolinium deposits. and The Consortium of MS Centers (CMSC) published an MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-up of MS. These guidelines address the safety concerns with GBCAs and make recommendations for when using a contrast agent is necessary.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Multiple Sclerosis Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Multiple Sclerosis Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Multiple Sclerosis Drugs, Suppliers of Multiple Sclerosis Drugs, Pharmaceutical Industry, Research Institutions, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Clinically Isolated Syndrome (CIS)
  • Relapsing-Remitting MS (RRMS)
  • Primary-Progressive MS (PPMS)
  • Secondary-Progressive MS (SPMS)
By Route of Administration
  • Injectable
  • Oral

By Distribution Channel
  • Online
  • Offline

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing instances of Multiple Sclerosis
      • 3.2.2. Increasing Awareness about health problems among people
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of Multiple Sclerosis Medication
    • 3.4. Market Trends
      • 3.4.1. Increased Spending on Health
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Multiple Sclerosis Drugs, by Type, Route of Administration, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Multiple Sclerosis Drugs (Value)
      • 5.2.1. Global Multiple Sclerosis Drugs by: Type (Value)
        • 5.2.1.1. Clinically Isolated Syndrome (CIS)
        • 5.2.1.2. Relapsing-Remitting MS (RRMS)
        • 5.2.1.3. Primary-Progressive MS (PPMS)
        • 5.2.1.4. Secondary-Progressive MS (SPMS)
      • 5.2.2. Global Multiple Sclerosis Drugs by: Route of Administration (Value)
        • 5.2.2.1. Injectable
        • 5.2.2.2. Oral
      • 5.2.3. Global Multiple Sclerosis Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Multiple Sclerosis Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Multiple Sclerosis Drugs (Volume)
      • 5.3.1. Global Multiple Sclerosis Drugs by: Type (Volume)
        • 5.3.1.1. Clinically Isolated Syndrome (CIS)
        • 5.3.1.2. Relapsing-Remitting MS (RRMS)
        • 5.3.1.3. Primary-Progressive MS (PPMS)
        • 5.3.1.4. Secondary-Progressive MS (SPMS)
      • 5.3.2. Global Multiple Sclerosis Drugs by: Route of Administration (Volume)
        • 5.3.2.1. Injectable
        • 5.3.2.2. Oral
      • 5.3.3. Global Multiple Sclerosis Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Online
        • 5.3.3.2. Offline
      • 5.3.4. Global Multiple Sclerosis Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Multiple Sclerosis Drugs (Price)
      • 5.4.1. Global Multiple Sclerosis Drugs by: Type (Price)
  • 6. Multiple Sclerosis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol Myers Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Genzyme Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck KGaA (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mallinckrodt (Unite States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Par Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cipla (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Multiple Sclerosis Drugs Sale, by Type, Route of Administration, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Multiple Sclerosis Drugs (Value)
      • 7.2.1. Global Multiple Sclerosis Drugs by: Type (Value)
        • 7.2.1.1. Clinically Isolated Syndrome (CIS)
        • 7.2.1.2. Relapsing-Remitting MS (RRMS)
        • 7.2.1.3. Primary-Progressive MS (PPMS)
        • 7.2.1.4. Secondary-Progressive MS (SPMS)
      • 7.2.2. Global Multiple Sclerosis Drugs by: Route of Administration (Value)
        • 7.2.2.1. Injectable
        • 7.2.2.2. Oral
      • 7.2.3. Global Multiple Sclerosis Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Multiple Sclerosis Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Multiple Sclerosis Drugs (Volume)
      • 7.3.1. Global Multiple Sclerosis Drugs by: Type (Volume)
        • 7.3.1.1. Clinically Isolated Syndrome (CIS)
        • 7.3.1.2. Relapsing-Remitting MS (RRMS)
        • 7.3.1.3. Primary-Progressive MS (PPMS)
        • 7.3.1.4. Secondary-Progressive MS (SPMS)
      • 7.3.2. Global Multiple Sclerosis Drugs by: Route of Administration (Volume)
        • 7.3.2.1. Injectable
        • 7.3.2.2. Oral
      • 7.3.3. Global Multiple Sclerosis Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Online
        • 7.3.3.2. Offline
      • 7.3.4. Global Multiple Sclerosis Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Multiple Sclerosis Drugs (Price)
      • 7.4.1. Global Multiple Sclerosis Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Multiple Sclerosis Drugs: by Type(USD Million)
  • Table 2. Multiple Sclerosis Drugs Clinically Isolated Syndrome (CIS) , by Region USD Million (2015-2020)
  • Table 3. Multiple Sclerosis Drugs Relapsing-Remitting MS (RRMS) , by Region USD Million (2015-2020)
  • Table 4. Multiple Sclerosis Drugs Primary-Progressive MS (PPMS) , by Region USD Million (2015-2020)
  • Table 5. Multiple Sclerosis Drugs Secondary-Progressive MS (SPMS) , by Region USD Million (2015-2020)
  • Table 6. Multiple Sclerosis Drugs: by Route of Administration(USD Million)
  • Table 7. Multiple Sclerosis Drugs Injectable , by Region USD Million (2015-2020)
  • Table 8. Multiple Sclerosis Drugs Oral , by Region USD Million (2015-2020)
  • Table 9. Multiple Sclerosis Drugs: by Distribution Channel(USD Million)
  • Table 10. Multiple Sclerosis Drugs Online , by Region USD Million (2015-2020)
  • Table 11. Multiple Sclerosis Drugs Offline , by Region USD Million (2015-2020)
  • Table 12. South America Multiple Sclerosis Drugs, by Country USD Million (2015-2020)
  • Table 13. South America Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 14. South America Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 15. South America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 16. Brazil Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 17. Brazil Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 18. Brazil Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 19. Argentina Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 20. Argentina Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 21. Argentina Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 22. Rest of South America Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 23. Rest of South America Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 24. Rest of South America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 25. Asia Pacific Multiple Sclerosis Drugs, by Country USD Million (2015-2020)
  • Table 26. Asia Pacific Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 27. Asia Pacific Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 28. Asia Pacific Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 29. China Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 30. China Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 31. China Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 32. Japan Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 33. Japan Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 34. Japan Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 35. India Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 36. India Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 37. India Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 38. South Korea Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 39. South Korea Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 40. South Korea Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 41. Taiwan Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 42. Taiwan Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 43. Taiwan Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 44. Australia Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 45. Australia Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 46. Australia Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 50. Europe Multiple Sclerosis Drugs, by Country USD Million (2015-2020)
  • Table 51. Europe Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 52. Europe Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 53. Europe Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 54. Germany Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 55. Germany Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 56. Germany Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 57. France Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 58. France Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 59. France Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 60. Italy Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 61. Italy Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 62. Italy Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 63. United Kingdom Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 64. United Kingdom Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 65. United Kingdom Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 66. Netherlands Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 67. Netherlands Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 68. Netherlands Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 69. Rest of Europe Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 70. Rest of Europe Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 71. Rest of Europe Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 72. MEA Multiple Sclerosis Drugs, by Country USD Million (2015-2020)
  • Table 73. MEA Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 74. MEA Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 75. MEA Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 76. Middle East Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 77. Middle East Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 78. Middle East Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 79. Africa Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 80. Africa Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 81. Africa Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 82. North America Multiple Sclerosis Drugs, by Country USD Million (2015-2020)
  • Table 83. North America Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 84. North America Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 85. North America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 86. United States Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 87. United States Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 88. United States Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 89. Canada Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 90. Canada Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 91. Canada Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 92. Mexico Multiple Sclerosis Drugs, by Type USD Million (2015-2020)
  • Table 93. Mexico Multiple Sclerosis Drugs, by Route of Administration USD Million (2015-2020)
  • Table 94. Mexico Multiple Sclerosis Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 95. Multiple Sclerosis Drugs Sales: by Type(K Tons)
  • Table 96. Multiple Sclerosis Drugs Sales Clinically Isolated Syndrome (CIS) , by Region K Tons (2015-2020)
  • Table 97. Multiple Sclerosis Drugs Sales Relapsing-Remitting MS (RRMS) , by Region K Tons (2015-2020)
  • Table 98. Multiple Sclerosis Drugs Sales Primary-Progressive MS (PPMS) , by Region K Tons (2015-2020)
  • Table 99. Multiple Sclerosis Drugs Sales Secondary-Progressive MS (SPMS) , by Region K Tons (2015-2020)
  • Table 100. Multiple Sclerosis Drugs Sales: by Route of Administration(K Tons)
  • Table 101. Multiple Sclerosis Drugs Sales Injectable , by Region K Tons (2015-2020)
  • Table 102. Multiple Sclerosis Drugs Sales Oral , by Region K Tons (2015-2020)
  • Table 103. Multiple Sclerosis Drugs Sales: by Distribution Channel(K Tons)
  • Table 104. Multiple Sclerosis Drugs Sales Online , by Region K Tons (2015-2020)
  • Table 105. Multiple Sclerosis Drugs Sales Offline , by Region K Tons (2015-2020)
  • Table 106. South America Multiple Sclerosis Drugs Sales, by Country K Tons (2015-2020)
  • Table 107. South America Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 108. South America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 109. South America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 110. Brazil Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 111. Brazil Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 112. Brazil Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 113. Argentina Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 114. Argentina Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 115. Argentina Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 116. Rest of South America Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 117. Rest of South America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 118. Rest of South America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 119. Asia Pacific Multiple Sclerosis Drugs Sales, by Country K Tons (2015-2020)
  • Table 120. Asia Pacific Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 121. Asia Pacific Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 122. Asia Pacific Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 123. China Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 124. China Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 125. China Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 126. Japan Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 127. Japan Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 128. Japan Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 129. India Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 130. India Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 131. India Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 132. South Korea Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 133. South Korea Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 134. South Korea Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 135. Taiwan Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 136. Taiwan Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 137. Taiwan Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 138. Australia Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 139. Australia Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 140. Australia Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 141. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 142. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 143. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 144. Europe Multiple Sclerosis Drugs Sales, by Country K Tons (2015-2020)
  • Table 145. Europe Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 146. Europe Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 147. Europe Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 148. Germany Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 149. Germany Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 150. Germany Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 151. France Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 152. France Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 153. France Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 154. Italy Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 155. Italy Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 156. Italy Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 157. United Kingdom Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 158. United Kingdom Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 159. United Kingdom Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 160. Netherlands Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 161. Netherlands Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 162. Netherlands Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 163. Rest of Europe Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 164. Rest of Europe Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 165. Rest of Europe Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 166. MEA Multiple Sclerosis Drugs Sales, by Country K Tons (2015-2020)
  • Table 167. MEA Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 168. MEA Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 169. MEA Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 170. Middle East Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 171. Middle East Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 172. Middle East Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 173. Africa Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 174. Africa Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 175. Africa Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 176. North America Multiple Sclerosis Drugs Sales, by Country K Tons (2015-2020)
  • Table 177. North America Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 178. North America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 179. North America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 180. United States Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 181. United States Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 182. United States Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 183. Canada Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 184. Canada Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 185. Canada Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 186. Mexico Multiple Sclerosis Drugs Sales, by Type K Tons (2015-2020)
  • Table 187. Mexico Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 188. Mexico Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 189. Multiple Sclerosis Drugs: by Type(USD/Units)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Multiple Sclerosis Drugs: by Type(USD Million)
  • Table 201. Multiple Sclerosis Drugs Clinically Isolated Syndrome (CIS) , by Region USD Million (2021-2026)
  • Table 202. Multiple Sclerosis Drugs Relapsing-Remitting MS (RRMS) , by Region USD Million (2021-2026)
  • Table 203. Multiple Sclerosis Drugs Primary-Progressive MS (PPMS) , by Region USD Million (2021-2026)
  • Table 204. Multiple Sclerosis Drugs Secondary-Progressive MS (SPMS) , by Region USD Million (2021-2026)
  • Table 205. Multiple Sclerosis Drugs: by Route of Administration(USD Million)
  • Table 206. Multiple Sclerosis Drugs Injectable , by Region USD Million (2021-2026)
  • Table 207. Multiple Sclerosis Drugs Oral , by Region USD Million (2021-2026)
  • Table 208. Multiple Sclerosis Drugs: by Distribution Channel(USD Million)
  • Table 209. Multiple Sclerosis Drugs Online , by Region USD Million (2021-2026)
  • Table 210. Multiple Sclerosis Drugs Offline , by Region USD Million (2021-2026)
  • Table 211. South America Multiple Sclerosis Drugs, by Country USD Million (2021-2026)
  • Table 212. South America Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 213. South America Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 214. South America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 215. Brazil Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 216. Brazil Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 217. Brazil Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 218. Argentina Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 219. Argentina Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 220. Argentina Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 221. Rest of South America Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 222. Rest of South America Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 223. Rest of South America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 224. Asia Pacific Multiple Sclerosis Drugs, by Country USD Million (2021-2026)
  • Table 225. Asia Pacific Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 226. Asia Pacific Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 227. Asia Pacific Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 228. China Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 229. China Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 230. China Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 231. Japan Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 232. Japan Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 233. Japan Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 234. India Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 235. India Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 236. India Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 237. South Korea Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 238. South Korea Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 239. South Korea Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 240. Taiwan Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 241. Taiwan Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 242. Taiwan Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 243. Australia Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 244. Australia Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 245. Australia Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 247. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 248. Rest of Asia-Pacific Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 249. Europe Multiple Sclerosis Drugs, by Country USD Million (2021-2026)
  • Table 250. Europe Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 251. Europe Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 252. Europe Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 253. Germany Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 254. Germany Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 255. Germany Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 256. France Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 257. France Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 258. France Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 259. Italy Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 260. Italy Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 261. Italy Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 262. United Kingdom Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 263. United Kingdom Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 264. United Kingdom Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 265. Netherlands Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 266. Netherlands Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 267. Netherlands Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 268. Rest of Europe Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 269. Rest of Europe Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 270. Rest of Europe Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 271. MEA Multiple Sclerosis Drugs, by Country USD Million (2021-2026)
  • Table 272. MEA Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 273. MEA Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 274. MEA Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 275. Middle East Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 276. Middle East Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 277. Middle East Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 278. Africa Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 279. Africa Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 280. Africa Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 281. North America Multiple Sclerosis Drugs, by Country USD Million (2021-2026)
  • Table 282. North America Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 283. North America Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 284. North America Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 285. United States Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 286. United States Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 287. United States Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 288. Canada Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 289. Canada Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 290. Canada Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 291. Mexico Multiple Sclerosis Drugs, by Type USD Million (2021-2026)
  • Table 292. Mexico Multiple Sclerosis Drugs, by Route of Administration USD Million (2021-2026)
  • Table 293. Mexico Multiple Sclerosis Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 294. Multiple Sclerosis Drugs Sales: by Type(K Tons)
  • Table 295. Multiple Sclerosis Drugs Sales Clinically Isolated Syndrome (CIS) , by Region K Tons (2021-2026)
  • Table 296. Multiple Sclerosis Drugs Sales Relapsing-Remitting MS (RRMS) , by Region K Tons (2021-2026)
  • Table 297. Multiple Sclerosis Drugs Sales Primary-Progressive MS (PPMS) , by Region K Tons (2021-2026)
  • Table 298. Multiple Sclerosis Drugs Sales Secondary-Progressive MS (SPMS) , by Region K Tons (2021-2026)
  • Table 299. Multiple Sclerosis Drugs Sales: by Route of Administration(K Tons)
  • Table 300. Multiple Sclerosis Drugs Sales Injectable , by Region K Tons (2021-2026)
  • Table 301. Multiple Sclerosis Drugs Sales Oral , by Region K Tons (2021-2026)
  • Table 302. Multiple Sclerosis Drugs Sales: by Distribution Channel(K Tons)
  • Table 303. Multiple Sclerosis Drugs Sales Online , by Region K Tons (2021-2026)
  • Table 304. Multiple Sclerosis Drugs Sales Offline , by Region K Tons (2021-2026)
  • Table 305. South America Multiple Sclerosis Drugs Sales, by Country K Tons (2021-2026)
  • Table 306. South America Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 307. South America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 308. South America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 309. Brazil Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 310. Brazil Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 311. Brazil Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 312. Argentina Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 313. Argentina Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 314. Argentina Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 315. Rest of South America Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 316. Rest of South America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 317. Rest of South America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 318. Asia Pacific Multiple Sclerosis Drugs Sales, by Country K Tons (2021-2026)
  • Table 319. Asia Pacific Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 320. Asia Pacific Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 321. Asia Pacific Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 322. China Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 323. China Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 324. China Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 325. Japan Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 326. Japan Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 327. Japan Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 328. India Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 329. India Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 330. India Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 331. South Korea Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 332. South Korea Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 333. South Korea Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 334. Taiwan Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 335. Taiwan Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 336. Taiwan Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 337. Australia Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 338. Australia Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 339. Australia Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 340. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 341. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 342. Rest of Asia-Pacific Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 343. Europe Multiple Sclerosis Drugs Sales, by Country K Tons (2021-2026)
  • Table 344. Europe Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 345. Europe Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 346. Europe Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 347. Germany Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 348. Germany Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 349. Germany Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 350. France Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 351. France Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 352. France Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 353. Italy Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 354. Italy Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 355. Italy Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 356. United Kingdom Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 357. United Kingdom Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 358. United Kingdom Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 359. Netherlands Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 360. Netherlands Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 361. Netherlands Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 362. Rest of Europe Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 363. Rest of Europe Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 364. Rest of Europe Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 365. MEA Multiple Sclerosis Drugs Sales, by Country K Tons (2021-2026)
  • Table 366. MEA Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 367. MEA Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 368. MEA Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 369. Middle East Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 370. Middle East Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 371. Middle East Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 372. Africa Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 373. Africa Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 374. Africa Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 375. North America Multiple Sclerosis Drugs Sales, by Country K Tons (2021-2026)
  • Table 376. North America Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 377. North America Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 378. North America Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 379. United States Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 380. United States Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 381. United States Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 382. Canada Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 383. Canada Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 384. Canada Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 385. Mexico Multiple Sclerosis Drugs Sales, by Type K Tons (2021-2026)
  • Table 386. Mexico Multiple Sclerosis Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 387. Mexico Multiple Sclerosis Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 388. Multiple Sclerosis Drugs: by Type(USD/Units)
  • Table 389. Research Programs/Design for This Report
  • Table 390. Key Data Information from Secondary Sources
  • Table 391. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Multiple Sclerosis Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Multiple Sclerosis Drugs: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Multiple Sclerosis Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 8. Asia Pacific Multiple Sclerosis Drugs Share (%), by Country
  • Figure 9. Europe Multiple Sclerosis Drugs Share (%), by Country
  • Figure 10. MEA Multiple Sclerosis Drugs Share (%), by Country
  • Figure 11. North America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 12. Global Multiple Sclerosis Drugs: by Type K Tons (2015-2020)
  • Figure 13. Global Multiple Sclerosis Drugs: by Route of Administration K Tons (2015-2020)
  • Figure 14. Global Multiple Sclerosis Drugs: by Distribution Channel K Tons (2015-2020)
  • Figure 15. South America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 16. Asia Pacific Multiple Sclerosis Drugs Share (%), by Country
  • Figure 17. Europe Multiple Sclerosis Drugs Share (%), by Country
  • Figure 18. MEA Multiple Sclerosis Drugs Share (%), by Country
  • Figure 19. North America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 20. Global Multiple Sclerosis Drugs: by Type USD/Units (2015-2020)
  • Figure 21. Global Multiple Sclerosis Drugs share by Players 2020 (%)
  • Figure 22. Global Multiple Sclerosis Drugs share by Players (Top 3) 2020(%)
  • Figure 23. Global Multiple Sclerosis Drugs share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 27. Genzyme Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Genzyme Corporation (United States) Revenue: by Geography 2020
  • Figure 29. Teva Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 31. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 33. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 35. Mallinckrodt (Unite States) Revenue, Net Income and Gross profit
  • Figure 36. Mallinckrodt (Unite States) Revenue: by Geography 2020
  • Figure 37. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 39. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 41. Par Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 42. Par Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 43. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 44. Cipla (India) Revenue: by Geography 2020
  • Figure 45. Global Multiple Sclerosis Drugs: by Type USD Million (2021-2026)
  • Figure 46. Global Multiple Sclerosis Drugs: by Route of Administration USD Million (2021-2026)
  • Figure 47. Global Multiple Sclerosis Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 48. South America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 49. Asia Pacific Multiple Sclerosis Drugs Share (%), by Country
  • Figure 50. Europe Multiple Sclerosis Drugs Share (%), by Country
  • Figure 51. MEA Multiple Sclerosis Drugs Share (%), by Country
  • Figure 52. North America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 53. Global Multiple Sclerosis Drugs: by Type K Tons (2021-2026)
  • Figure 54. Global Multiple Sclerosis Drugs: by Route of Administration K Tons (2021-2026)
  • Figure 55. Global Multiple Sclerosis Drugs: by Distribution Channel K Tons (2021-2026)
  • Figure 56. South America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 57. Asia Pacific Multiple Sclerosis Drugs Share (%), by Country
  • Figure 58. Europe Multiple Sclerosis Drugs Share (%), by Country
  • Figure 59. MEA Multiple Sclerosis Drugs Share (%), by Country
  • Figure 60. North America Multiple Sclerosis Drugs Share (%), by Country
  • Figure 61. Global Multiple Sclerosis Drugs: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Bristol Myers Squibb (United States)
  • Genzyme Corporation (United States)
  • Teva Pharmaceuticals (United States)
  • Roche Holding AG (Switzerland)
  • Merck KGaA (Germany)
  • Mallinckrodt (Unite States)
  • Pfizer Inc (United States)
  • Hikma Pharmaceuticals PLC (United Kingdom)
  • Par Pharmaceuticals (United States)
  • Cipla (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation